Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05850130 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Acupuncture for Oxaliplatin-induced Peripheral Neuropathy in Gastro-intestinal Cancer Patients

Study acronym: ACUPOX
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 5 → 15 locations
    • Eligibility criteria expanded, about 19 words
    v6
  2. Re-verified, no change to tracked fieldsv5
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2023 to Nov 22, 2023
    • Site details revised at 5 of 5 sites
    v4
  4. Phase: Phase 2 to Not applicable
    • Start date: May 2023 to Sep 2023
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints revised (4)
    v3
  5. Secondary endpoints: details revised at 1 of 4 entries
    • Study title shortened, about 8 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ACUPOX is a multicenter, open label, 2-cohort based phase II clinical study evaluating the interest of a standardized protocol of verum acupuncture in treatment of Oxaliplatin-induced peripheral neuropathy in patients with gastro-intestinal solid tumors who discontinued oxaliplatin-containing chemotherapy.
Trial Details
NCT Number NCT05850130
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Conditions
(from sponsor)		 Colorectal Cancer, Liver Cancer, Gastric Cancer, Pancreas Cancer, Esophagus Cancer
Related terms Colorectal Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Enrollment 182 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov